Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances
Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals Abstract honored with prestigious "Abstracts of...